Company

We aim at providing better care for brain injured patients.

Who are we ?

BrainTale is an innovative company opening a new era in medicine by providing physicians with clinically validated prognostic solutions for the management of brain injured patients through sensitive and reliable measurements of brain white-matter microstructure alterations. Building on more than 15 years in clinical development, BrainTale’s products are developed collaboratively to address medical need and fulfil expectations of healthcare professionals and patients alike. Since its inception in 2018, the company has set up a complete quality management system and is now ISO:13485:2016 certified, with a suite of products available on the European market.

Our Values

Excellence of science

Patient benefit

Clinical validation

Quality controlled

Executive Team

Julie Rachline

Co-founder, Julie has increased her contribution to Braintale in 2020 where she took CEOship and neurology franchise head since 2021. PhD in Neuropharmacology, Julie has more than a decade of experience as an early-stage and growth capital investor in France and Europe combined with two years as a headhunter. In 2015, she founded LallianSe an equity stories builder, of which Braintale is the flagship company. Julie is also leader of Invest Health, the service affiliate of EIT Health, and independent board member of DTA Medical, Virdis and TechToMed.

Vincent Perlbarg

Co-founder, Vincent has been Braintale’spresident and Chief Scientific Officer since 2018. He has both engineer degree from Grenoble INP and PhD in Medical Physics in 2007 from Paris XI University. Thorough his research, at Sorbonne Universiy and Brain and Spine Institute (ICM, Paris) he authored more than 70 articles (h-index = 29) on advanced methods for neuroimaging data analysis in neuroscience and in various clinical applications as traumatic brain injuries, stroke or neurodegenerative diseases.

Dorothée Uriet

Dorothée has joined Braintale in 2018, where she is now in charge of commercial deployment and clinical affairs. Dorothée holds of a MSc in pharma-biotech from the Faculty of Pharmacy of Reims. With more than 15 years of experience with knowledge of the regulatory environment, market access and business development, she served in various positions for 12 years in clinical operations in diverse organisations from medical devices companies to CROs, both in Europe and in the US.

Jean-Baptiste Martini

Jean-Baptiste joined BrainTale in 2021. With more than 15 years of experience in medical imaging software, he is in charge of products development . Jean-Baptiste co-founded Qynapse and served as the imaging R&D leader, in charge of the development, certification and roll-out of Qynapse software for image analysis and processing. He also was software engineer for the neuroimaging platform CATI and worked at Dosisoft. Jean-Baptiste holds a master’s in artificial intelligence from Sorbonne University, Paris.

Strategic board

Spyros Artavanis-Tsakonas

Professor Spyros Artavanis-Tsakonas is Professor Emeritus in the Department of Cell Biology at Harvard Medical School. In 1999, he was elected Professor at the Collège de France, holding the Chair of Biology and Genetics of Development until 2012 when he became Professeur honoraire. He is the Founding Director of the Department of Genetics and Developmental Biology at Institut Curie, Paris. From 2012 to March 2017, he served as Chief Scientific Officer and Executive Vice President at Biogen Inc.
He is a fellow of the American Academy of Arts and Sciences, an associate member of EMBO, and a corresponding member of the Academy of Athens and a member of the Cambridge Philosophical Society, co-founder and president of Fondation Sante, a charitable organization supporting Biomedical research in Greece, and co-founder of Exelixis, Cellzome and Anadys.

Nitza Thomasson

Dr Nitza Thomasson is the co-founder of Gensight Biologics (Gene therapy for ophthalmologic diseases) and BrainEver (Advanced medicinal products to treat neurodegenerative diseases). After a post doc at Northwestern & Rush University (Chicago, USA), she joined the pharma industry to develop medicines for neurologic and psychiatric disorders at Servier. Then she moved to the biotech world, joining Fovea Pharma in 2009, that became Ophthalmology Division of Sanofi. She contributed to the start of Tissium (2014 - Head of Development), while co-founding GenSight Biologics (2013 - Preclinical and CMC Officer), then BrainEver (2015 - Chief Operating Officer). In 2018, Nitza founded NtzConsulting.
Nitza is also Venture Partner at OmnesCapital. She is board member to support innovation and growth in the healthcare company portfolio.

Eric Garnier

Eric Garnier has 35 years of experience in healthcare and medical devices management, acquired in multinational industries (BMS, Danaher) including more than a decade of expatriation in London, Singapore and Boston. Today he is an advisor and belongs to the Angels Santé’s bureau.

Julien Vandewalle

Member of the Paris Business Angels network, Julien Vandewalle held managerial positions at international level within leading Medtech and Pharma groups (Medtronic, Edwards, Eli Lilly), and specializes in the commercial launch of connected health products.

Louis Puybasset

Louis Puybasset is the head of the Pitié-Salpêtrière Department of Anesthesiology and Intensive Care since Sept. 2017. He was previously the Head of the Neuro-Intensive care and Neuroanesthesia since Oct 99.
He has devoted his scientific work in the last years to the prediction of the outcome from coma using a multimodal approach combining biological markers, the use of EEG, quantitative CT and MRI.
He is the PI of a multicentric study using DTI and MRS to predict the one year outcome based on clinical data and early MRI. This study started in 2006 and has included more than 1400 patients in 30 centers.
Louis Puybasset has also been implicated from 2004 in the legislation regarding the end of life in France. He is the coordinator of a textbook on medical ethics in the ICU and the co-author of a general public book on euthanasia.

Vincent Perlbarg

Co-founder, Vincent has been Braintale’s president and Chief Scientific Officer since 2018. He has both engineer degree from Grenoble INP and PhD in Medical Physics in 2007 from Paris XI University. Thorough his research, at Sorbonne Universiy and Brain and Spine Institute (ICM, Paris) he authored more than 70 articles (h-index = 29) on advanced methods for neuroimaging data analysis in neuroscience and in various clinical applications as traumatic brain injuries, stroke or neurodegenerative diseases.

Julie Rachline

Co-founder, Julie has increased her contribution to Braintale in 2020 where she took CEOship and neurology franchise head since 2021. PhD in Neuropharmacology, Julie has more than a decade of experience as an early-stage and growth capital investor in France and Europe combined with two years as a headhunter. In 2015, she founded LallianSe an equity stories builder, of which Braintale is the flagship company. Julie is also leader of Invest Health, the service affiliate of EIT Health, and independent board member of DTA Medical, Virdis and TechToMed.